Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1881 1
2002 2
2003 3
2004 3
2005 2
2006 4
2007 3
2008 9
2009 6
2010 4
2011 10
2012 8
2013 6
2014 5
2015 9
2016 12
2017 11
2018 4
2019 5
2020 7
2021 6
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34969743

107 results

Results by year

Filters applied: . Clear all
Page 1
Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.
Nagai H, Kitano T, Nishimura T, Yasuda H, Nakata K, Takashima S, Kanai M, Matsumoto S, Mori Y, Kakudo Y, Sato H, Yamaguchi T, Kameno K, Kim YH, Mishima M, Yanagihara K. Nagai H, et al. Support Care Cancer. 2013 Dec;21(12):3271-8. doi: 10.1007/s00520-013-1901-9. Epub 2013 Jul 23. Support Care Cancer. 2013. PMID: 23877927 Clinical Trial.
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Louvet C, et al. J Clin Oncol. 2005 May 20;23(15):3509-16. doi: 10.1200/JCO.2005.06.023. J Clin Oncol. 2005. PMID: 15908661 Clinical Trial.
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer. Lee HS, et al. Medicine (Baltimore). 2017 Jan;96(1):e5702. doi: 10.1097/MD.0000000000005702. Medicine (Baltimore). 2017. PMID: 28072706 Free PMC article. Clinical Trial.
Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA, Nesbitt H, Callan B, Gao J, McKaig T, Taylor M, Love M, McHale AP, Callan JF. Logan KA, et al. Eur J Pharm Biopharm. 2021 Aug;165:374-382. doi: 10.1016/j.ejpb.2021.05.018. Epub 2021 May 24. Eur J Pharm Biopharm. 2021. PMID: 34038797
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. Poplin E, et al. J Clin Oncol. 2009 Aug 10;27(23):3778-85. doi: 10.1200/JCO.2008.20.9007. Epub 2009 Jul 6. J Clin Oncol. 2009. PMID: 19581537 Free PMC article. Clinical Trial.
107 results